Phase I trial of adjuvant chemotherapy w
β
Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry
π
Article
π
1988
π
Springer US
π
English
β 263 KB
Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w